Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Albumin-bound Paclitaxel Combined With Carboplatin Versus Epirubicin Combined With Docetaxel as Neoadjuvant Therapy for Triple-negative Breast Cancer: a Multicenter Randomized Controlled Phase IV Clinical Trial

NCT04136782 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT04136782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04136782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Albumin-bound Paclitaxel Combined With Carboplatin Versus Epirubicin Combined With Docetaxel as Neoadjuvant Therapy for Triple-negative Breast Cancer: a Multicenter Randomized Controlled Phase IV Clinical Trial
Lead sponsor
Shengjing Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
July 19, 2021
Completion date
November 30, 2026
Enrollment
110 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer